Brief: Nicox: Enrollment Progress In Mont Blanc Phase 3 Clinical Trial

Nicox SA

15/07/2020 06:39

July 15 (Reuters) - Nicox SA  NCOX.PA :
    * NICOX REPORTS ON ENROLLMENT PROGRESS IN MONT BLANC PHASE 3
CLINICAL TRIAL IN GLAUCOMA
    * OVER FORTY CLINICAL SITES HAVE BEEN INITIATED IN FIRST
MONTH IN
NCX 470 MONT BLANC PHASE 3 CLINICAL TRIAL
    * NCX 470 MONT BLANC PHASE 3 TRIAL IS ON TRACK TO SUPPORT
ADAPTIVE
DOSE SELECTION BY END OF 2020
    * SECOND NCX 470 PHASE 3 TRIAL, DENALI, IS ON TRACK TO START
BY
END OF 2020
    * DUE TO POTENTIAL DELAYS CAUSED BY COVID-19, COMPANY NOT
CURRENTLY PROVIDING TARGET DATE FOR MONT BLANC TOPLINE RESULTS
    * WE CURRENTLY DO NOT ANTICIPATE DELAYS TO OUR CLINICAL
TIMELINES

Source text for Eikon:  ID:nGNX8cKLyt 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))